Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 11/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.53 |
| ▸ | KDR | P35968 | 12/20 | 0.51 |
| ▸ | MET | P08581 | 5/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 3/20 | 0.51 |
| ▸ | TEK | Q02763 | 3/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 10/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22407328 | 0.90 | KDR (0.50) | PDGFRBPDGFRAKDRMETIGF1R | |
| SCHEMBL22407488 | 0.89 | AXL (0.54) | PDGFRAKDRMETAURKATEK | |
| SCHEMBL22407425 | 0.89 | KDR (0.50) | PDGFRBPDGFRAKDRMETIGF1R | |
| SCHEMBL22407308 | 0.86 | KDR (0.47) | PDGFRBPDGFRAKDRMETIGF1R | |
| SCHEMBL20775123 | 0.84 | FGFR2 (0.57) | PDGFRAKDRMETAURKATEK | |
| SCHEMBL22407371 | 0.82 | KDR (0.51) | PDGFRBPDGFRAKDRMETIGF1R | |
| SCHEMBL20782454 | 0.82 | AXL (0.54) | PDGFRBPDGFRAKDRMETIGF1R | |
| SCHEMBL22407378 | 0.81 | ENPP1 (0.53) | PDGFRBPDGFRAKDRMETIGF1R | |
| SCHEMBL22407406 | 0.81 | HTR1A (0.44) | PDGFRAKDRMETIGF1RAURKA | |
| SCHEMBL22407551 | 0.81 | FGFR2 (0.53) | PDGFRBPDGFRAKDRCSF1RFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | PDGFRB 488/4885PDGFRA 624/4885KDR 2584/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | PDGFRB 488/4885PDGFRA 624/4885KDR 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.